08:00 – 09:00
GECP GENERAL ASSEMBLY
08:15 – 09:15
SESSION VII: OTHER DRIVERS MUTATIONS IN LUNG CANCER
| Chairs | Dr. Bartomeu Massutí Hospital General Univ. Dr. Balmis, Alicante Dr. Teresa Morán ICO, Hospital Univ. Germans Trias i Pujol, Badalona, Barcelona |
| 09:00 - 09:15 | New insights in KRAS mutation Dr. Miriam Molina-Arcas Francis Crick Institute, London (UK) |
| 09:15 - 09:30 | Resistance pathways to RAS inhibition Dr. Rafael Rosell Instituto Oncológico Dr Rosell, Barcelona |
| 09:30 - 09:45 | BRAF mutations: Small changes, big impact Dr. Joaquim Bosch ICO, Hospital Univ. Dr. Josep Trueta, Girona |
| 09:45 - 10:00 | HER2: A new frontier in precision oncology Dr. Ernest Nadal ICO, Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona |
| 10:00 - 10:15 | Fusions in lung cancer Dr. Rosario García Campelo Hospital Univ. de A Coruña |
| 10:15 - 10:30 | Discussion |
10:30 – 11:30
SESSION VIII: PROFFERED POSTER
11:30 – 12:00
Coffee Break
12:00 – 13:15
SESSION IX: NEW DRUGS DEVELOPMENT IN NSCLC LUNG CANCER
| Chairs | Dr. Antonio Calles Hospital General Univ. Gregorio Marañón, Madrid Dr. Xabier Mielgo Hospital Univ. Fundación Alcorcón, Madrid |
| 12:00 - 12:15 | Treating resistance mechanisms in oncogenic diseases Dr. Óscar Juan-Vidal Hospital Univ. y Politécnico La Fe, Valencia |
| 12:15 - 12:30 | Is the future conjugated? ADCs in lung cancer treatment Dr. Francesca Fusco IRCCS - Istituto Nazionale Tumori Regina Elena, Rome (Italy) |
| 12:30 - 12:45 | Biospecifics antibodies: BITES/TRITES Dr. Biagio Ricciuti Dana-Farber Cancer Institute, Boston (USA) |
| 12:45 - 13:00 | Other immunotherapy strategies: Vaccines, cellular therapy, oncolytic virus Dr. Enriqueta Felip Hospital Univ. Vall d'Hebron, Barcelona |
| 13:00 - 13:15 | Discussion |
13:15 – 14:40
Lunch
13:15 – 14:40
LUNCH SATELLITE SYMPOSIUM
14:40 – 15:55
SESSION X: SCLC, NEUROENDOCRINE AND MESOTHELIOMA
| Chairs | Dr. Manuel Dómine Hospital Univ. Fundación Jiménez Díaz, Madrid Dr. María Ángeles Sala Hospital de la Santa Creu i Sant Pau, Barcelona |
| 14:40 - 14:55 | Changing landscape in SCLC limited disease Dr. Anna Estival Hospital Univ. Insular de Gran Canaria, Las Palmas |
| 14:55 - 15:10 | New strategies in SCLC metastatic disease Dr. Edurne Arriola Hospital del Mar, Barcelona |
| 15:10 - 15:25 | Large cell neuroendocrine new insights Dr. Noemí Reguart Hospital Clínic Barcelona |
| 15:25 - 15:40 | Systemic treatment in mesothelioma Dr. Jarushka Naidoo Beaumont Hospital and RCSI University of Health Sciences, Dublin (Ireland) |
| 15:40 - 15:55 | Discussion |
15:55 – 17:10
SESSION XI: IMMUNOTHERAPY
| Chairs | Dr. Javier de Castro Hospital Univ. La Paz, Madrid Dr. Delvys Rodríguez-Abreu Hospital Univ. Insular de Gran Canaria, Las Palmas |
| 15:55 - 16:10 | How to choose immunotherapy agent/s in first line Dr. Martín Lázaro Complejo Hospitalario Univ. de Vigo |
| 16:10 - 16:25 | Microbiota role in immunotherapy efficacy Dr. Laurence Zitvogel Institut Gustave-Roussy, Villejuif (France) |
| 16:25 - 16:40 | Optimization of IO treatment: Administration schedule, circadian rhythms... Dr. Sergio Vázquez Hospital Univ. Lucus Augusti, Lugo |
| 16:40 - 16:55 | Consolidation RT in metastatic disease without oncogenic driver Dr. Amelia Insa Hospital Clínico Univ. de Valencia |
| 16:55 - 17:10 | Discussion |